AC Immune (ACIU) Gains from Investment Securities (2019)
AC Immune (ACIU) posted quarterly Gains from Investment Securities of -$36900.4 for Q2 2019, up 99.18% quarter-over-quarter from -$4.5 million in Q1 2019.
AC Immune (ACIU) Gains from Investment Securities (2019) Analysis & Trends
AC Immune (ACIU) has reported Gains from Investment Securities for 1 consecutive years, with -$36900.4 the latest figure, recorded in Q2 2019.
- In Q2 2019, Gains from Investment Securities changed N/A year-over-year to -$36900.4; the TTM figure through Sep 2025 stood at -$36900.4 (changed N/A YoY), while the FY2025 annual figure was -$18091.9, changed N/A from the prior year.
- Gains from Investment Securities rose to -$36900.4 in Q2 2019 per ACIU's latest filing, from -$4.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$36900.4 in Q2 2019 and bottomed at -$4.5 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -36,900.39 |
| Jun 30, 2019 | -36,900.39 |
| Mar 31, 2019 | -4.52 Mn |
| Mar 31, 2019 | -4.52 Mn |